Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Clinical trial NCT02290951 · COMPLETED
Trial details
- NCT number
- NCT02290951
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-09
- Primary completion
- 2025-08-21
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.